Pancreatic Cancer Clinical Trial
Official title:
A Phase 1 Feasibility Study of Cholesterol Metabolism Reprogramming (Evolocumab, Atorvastatin and Ezetimibe) in Combination With the Standard of Care in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Verified date | May 2024 |
Source | CHU de Quebec-Universite Laval |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression. All cells require cholesterol, but cancer cells have much higher needs to sustain growth, division and metastasis. The availability of new cholesterol-lowering drugs developed to protect patients from heart diseases has resulted in unprecedented low levels of cholesterol. The combination of atorvastatin, ezetimibe and Repatha, which are 3 cholesterol-lowering drugs used in combination, is safe, well tolerated and efficient over years of treatment. Recent reports indicate that abundant cholesterol supplies are required to sustain the progression of pancreatic ductal adenocarcinomas. This proof-of-concept study aims to verify the feasibility, the acceptability and gain preliminary data on adding a cholesterol shortage on top of FOLFIRINOX (standard chemotherapy) in newly diagnosed patients with locally advanced pancreatic adenocarcinomas or metastatic pancreatic adenocarcinomas. It is expected that a drug-induced cholesterol shortage will slow-down or stop the progression of pancreatic adenocarcinomas while increasing the response to chemotherapy.
Status | Active, not recruiting |
Enrollment | 3 |
Est. completion date | December 31, 2026 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: To be eligible to this trial, patients must fulfill the following inclusion criteria: 1. Have a histologically confirmed, treatment-naive locally advanced and inoperable (LaiPDAC) or metastatic pancreatic ductal adenocarcinoma (mPDAC). 2. Be at least 18 years or older at the time of signing the informed consent. 3. Have a life expectancy of at least 12 weeks. 4. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. 5. Have measurable disease as assessed by RECIST v1.1. 6. Agrees and amenable to a tumor (if deemed safe only) and liver biopsy (all participants) at baseline and on day 42 +/- 3 days. Patient that are anticoagulated at baseline are eligible provided it is deemed safe by the investigator to stop anticoagulation momentarily in order to safely proceed to a biopsy. 7. Eligible to standard-dose FOLFIRINOX as assessed by the principal investigator or a sub-investigator. FOLFIRINOX doses can be adapted according to SOC. 8. Demonstrate normal organ function as defined below. These assessments must be done within 7 days of Cycle 1 Day-7. Hemoglobin (Hb) = 90 g/L Absolute neutrophil count = 1.5 x 10 9/L Platelet count = 100 x 10 9/L INR = 1.3 (unless patient is anticoagulated*) aPTT = 1.5 x ULN (switching to LMWH will be recommended) Total bilirubin = 1.5 x ULN OR Direct bilirubin (for patients with total bilirubin = 1.5 x ULN) AST and ALT = 3 x ULN CPK = 1.5 x ULN Serum creatinine = 1.5 x ULN OR Estimated GFR (as per institutional standards) = 50 ml/min 9. Provide written informed consent and able to follow the trial treatment and visit schedule. 10. For Women Of Child-Bearing Potential (WOCBP), a negative serum pregnancy test must be obtained prior to receiving the study medication. 11. WOCBP should agree to use 2 different methods of birth control OR abstain from heterosexual intercourse for the duration of the trial and up to 90 days after the last study medication administration. 12. Male subjects should agree to use an adequate method of contraception for the duration of the trial and up to 90 days after the last study medication administration. Male subjects should refrain from donating sperm during this period. Exclusion Criteria: To be eligible to this trial, patients must not fulfill any of the following exclusion criteria: 1. Locally advanced pancreatic ductal adenocarcinoma deemed operable. 2. Any pancreatic ductal adenocarcinoma deemed operable or borderline operable that can be treated with neoadjuvant chemotherapy. 3. Known additional malignancy that is progressing or that requires treatment. Exceptions include basal cell carcinoma of the skin, in situ bladder or in situ cervical cancer. Other malignancy may be eligible after consultation with the promotor-investigator. 4. Spinal cord compression or brain metastases unless treated, stable and not requiring steroids for at least 4 weeks prior to the initiation of study treatment. 5. Baseline myalgia or myositis of any etiology. 6. Prior treatment with FOLFIRINOX in the adjuvant setting. 7. History of clinically significant intolerance or myositis with any statin. 8. History of clinically significant intolerance or hypersensitivity to PCSK9 inhibitors or ezetimibe. 9. Baseline grade = 2 ULN Creatine Phosphokinase (CPK) elevation. 10. Liver tumor burden that is deemed unsafe by the investigator. 11. Major surgery or procedure from which the patient has not yet recovered. 12. Any medical condition that puts the patient at high medical risk, including but not limited to active uncontrolled infection or active bleeding diathesis. 13. Any history of disease that, in the opinion of the investigator, puts liver function at risk including but not limited to autoimmune hepatitis or history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Screening at baseline for those conditions is not required. 14. Use of any drugs that are contraindicated as per protocol and that cannot be changed or modified to an acceptable alternative. 15. Active smoker. Complete usage of tobacco must have been stopped for at least 3 months. 16. Abnormally low hematocrit, as assessed by the oncologist. |
Country | Name | City | State |
---|---|---|---|
Canada | CHUM | Montreal | Quebec |
Canada | CHU de Québec-Université Laval | Quebec city | Quebec |
Lead Sponsor | Collaborator |
---|---|
CHU de Quebec-Universite Laval | Biovalorem, Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Investigation of changes in the lipid profile induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. | Changes in Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides using serial assessment. All measures are in mmol/L. | 1 year | |
Other | Investigation of changes in circulating apo B levels induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. | Changes in Apolipoprotein B (g/L) using serial assessment. | 1 year | |
Other | Investigation of changes in Apo A1 levels induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. | Changes in Apolipoprotein A1 (g/L) using serial assessment. | 1 year | |
Other | Investigation of changes in PCSK9 induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. | Changes in total, free and phosphorylated PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, ng/L) levels using serial assessment (measured by mass spectrometry). | 1 year | |
Other | Efficacy as measured by objective response rate | To obtain a preliminary assessment of the efficacy of the combination of cholesterol metabolism disruption and FOLFIRINOX: tumoral response assessment will be centrally Evaluated using RECIST v1.1. | 1 year | |
Other | Efficacy as measured by overall survival | Overall Survival (OS) at 1 year | 1 year | |
Other | Efficacy as measured by progression free survival | Progression Free Survival (PFS) at 1 year | 1 year | |
Other | Investigation of changes in insulin, phytosterols, ANGPTL3, ANGPTL4, ANGPTL8 and Apo C3 levels induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. | Changes in insulin, phytosterols, ANGPTL3, ANGPTL4, ANGPTL8 and Apo C3 levels | 1 year | |
Other | To explore the feasibility of a larger multicenter trial | Collect preliminary data permitting to obtain estimates for the feasibility of a larger multicenter trial :
Recruitment time Retention and dropout rates Acceptability of the regimen as assessed by patients Dose-limiting toxicities Response of biomarkers RECIST assessment Estimates for overall response rate (ORR) Estimates of progression-free survival (PFS) at 1 year Estimates of median overall survival (mOS) Monitor adverse effects Identification of missing data Identification of barriers to study completion Estimates to guide samples size / power calculation for a larger multicenter trial |
1 year | |
Primary | Safety as measured by the rate of adverse events | To determine causality and grading severity of each adverse event (AEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. | 2 years | |
Primary | Characterization of dose-limiting toxicities | To determine the dose at which no more than 1 out of 6 patients experience a drug related dose-limiting toxicity. To confirm that the combination of daily atorvastatin 40 mg, ezetimibe 10 mg twice daily and monthly evolocumab 420 mg meets the criterion to be the recommended phase II dose (RP2D). | 2 years | |
Secondary | LDLR (low-density lipoprotein receptor) tumoral and hepatic changes in response to the multipathway cholesterol embargo. | Assessment of the level of LDLR in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. | 1 year | |
Secondary | LRP1 (Low-density lipoprotein Receptor-Related Protein 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo. | Assessment of the level of LRP1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. | 1 year | |
Secondary | NPC1L1 (Niemann-Pick C1-Like 1 protein) tumoral and hepatic changes in response to the multipathway cholesterol embargo. | Assessment of the level of NPC1L1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. | 1 year | |
Secondary | SRB1 (Scavenger Receptor class B type 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo. | Assessment of the level of SRB1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. | 1 year | |
Secondary | MHC-1 (Major Histocompatibility Complex class 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo. | Assessment of the level of MHC-1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry | 1 year | |
Secondary | PD-L1 (Programmed Death-Ligand-1) changes in response to the multipathway cholesterol embargo. | Assessment of the level of PD-L1 (Programmed Death-Ligand-1) in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. | 1 year | |
Secondary | Change in tumoral and hepatic levels of TILs (Tumor-Infiltrating Lymphocytes) | Assessment of tumoral and hepatic levels of TILs by immunohistochemistry | 1 year | |
Secondary | CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo | Assessment of tumoral and hepatic levels in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|